Activated PRP for Treatment of Androgenetic Alopecia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Androgenetic Alopecia
Interventions
BIOLOGICAL

Autologous platelet-rich plasma

PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.

Trial Locations (1)

01803

Lahey Hospital and Medical Center, Burlington

All Listed Sponsors
lead

Santiste Medical Inc.

INDUSTRY